(marketscreener.com) 20 December…

Cardinal Health(marketscreener.com) 20 December 2021. Telix Pharmaceuticals Limited , a global biopharmaceutical company focused on the development of diagnostic and therapeutic products based on molecularly targeted radiation , today announces that the United States Food and Drug Administration has approved Telix’s lead prostate cancer imaging product, Illuccix®.
Source

Hippo Sighting Report

Help us out, we really appreciate it.

Help contribute to our research, and let us know if you have seen similar situations that we may have missed. Our team will review the details you provide and add to our main list once we verify the information.

stay informed

Subscribe and get the updated Hippo List.

Get notified when we release our updated lists by email.

Make a Donation

Thank you for subscribing!

We will send you an email to confirm your details.  Welcome aboard!

Thanks for sending us your report.

We will review your information, and publish in on our list once we validate the details.